Sartorius Stedim Biotech Shares Mark a 6th Consecutive Session of Gains Targeting €188
The French bioproduction equipment specialist confirms its recovery in late afternoon trading. The stock continues its upward trend started last week, in a generally well-oriented SBF 120 index.
The Stock Crosses its 50-Day Moving Average with a Weekly Gain of Over 6%
SARTORIUS STED BIO stock rises 1.88% to €173.40, extending a recovery movement that brings the weekly performance to 6.32%. The price clearly moves above its 50-day moving average (€167.31), with a gap of 3.64%, after having already crossed its 20-day moving average (€160.94) in previous sessions. The RSI at 57 indicates a strengthening buying momentum without yet signaling any tension. However, the 200-day moving average remains 6.39% above the current price at €185.23, reminding that the stock has not yet erased its annual decline of 12.53%. Today's rebound partially reduces the three-month accumulated decline of -5.12%, without fully offsetting it.
A Recovery Initiated After First Quarter Results Punishment
The recent sessions' upward trend follows a sharp correction after the first quarter 2026 results were published on April 23. The company reported a revenue of €762 million, up 7.9% at constant exchange rates, but a slight decline in current EBITDA margin to 30.7% from 30.8% a year earlier. The stock then plummeted to €153 at the end of April, below the lower Bollinger Band. Since then, the price has regained more than 13% and has moved out of the oversold zone. The market context is supportive during the session, with the CAC 40 up by 0.4% and the SBF 120 gaining 0.42%. The next significant resistance is at €188.70, approximately corresponding to the 200-day moving average.
